Explore how EZH2 inhibition represents a promising epigenetic therapy approach for treating medulloblastoma, the most common pediatric brain tumor.
Discover how SETD8 research is revolutionizing treatment for MYC-driven medulloblastoma, the most aggressive childhood brain cancer.